The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae

Journal of Infectious Diseases

Volumn 191, Issue 9, 2005, Pages 1538-1547

  Kirby, Alun C ^a,b   Raynes, John G ^a   Kaye, Paul M ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN P75; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR IMMUNOGLOBULIN FUSION PROTEIN P75P SF3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DEATH; EXPERIMENTAL INFECTION; GENE DELETION; INFECTION RESISTANCE; LIVER; MALE; MOUSE; NONHUMAN; PARAMETER; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC DISEASE;

ANIMALS; LUNG; MALE; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; NEUTROPHILS; PHAGOCYTES; PNEUMOCOCCAL INFECTIONS; SPLEEN; STREPTOCOCCUS PNEUMONIAE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17644411973     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/429296     Document Type: Article

References (44)

1. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002; 51:98-104.
2. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003; 9:424-30.
3. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35.
4. Gingles NA, Alexander JE, Kadioglu A, et al. Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun 2001; 69:426-34.
5. Kerr AR, Irvine JJ, Search JJ, et al. Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect Immun 2002; 70:1547-57.
6. Rijneveld AW, Florquin S, Branger J, Speelman P, Van Deventer SJ, van der Poll T. TNF-α compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 2001; 167:5240-6.
7. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997; 65:257-60.
8. Lauw FN, Branger J, Florquin S, et al. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol 2002; 168:372-8.
9. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176:439-44.
10. Wellmer A, Gerber J, Ragheb J, et al. Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun 2001; 69:6881-6.
11. O'Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 1999; 67:595-601.
12. Benton KA, VanCott JL, Briles DE. Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect Immun 1998; 66:839-42.
13. Ansfield MJ, Woods DE, Johanson WG Jr. Lung bacterial clearance in murine pneumococcal pneumonia. Infect Immun 1977; 17:195-204.
14. Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66:912-22.
15. Bruyn GA, Zegers BJ, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992; 14:251-62.
16. + natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol 2003; 33:3322-30.
17. Scott KA, Moore RJ, Arnott CH, et al. An anti-tumor necrosis factor-α antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003; 2:445-51.
18. Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, Ghrayeb J. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 1995; 7:759-70.
19. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-8.
20. + T cells expressing NK cell receptors in influenza A virus-infected mice. J Immunol 2000; 165:4964-9.
21. Kirby AC, Yrlid U, Svensson M, Wick MJ. Differential involvement of dendritic cell subsets during acute Salmonella infection. J Immunol 2001; 166:6802-11.
22. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257:548-51.
23. Asselin-Paturel C, Boonstra A, Dalod M, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2:1144-50.
24. Constant SL, Brogdon JL, Piggott DA, et al. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest 2002; 110:1441-8.
25. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 2003; 48:3013-22.
26. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Mattesen EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76:653-6.
27. Wang E, Simard M, Ouellet N, Bergeron Y, Beauchamp D, Bergeron MG. Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice. Infect Immun 2002; 70:4226-38.
28. Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo. Am J Respir Cell Mol Biol 1995; 12:232-7.
29. Frisch AW, Tripp TJ, Barrett CD Jr, Pidgeon BE. The specific polysaccharide content of pneumonic lungs. J Exp Med 1942; 76:505-10.
30. Kadioglu A, Taylor S, Iannelli F, Pozzi G, Mitchell TJ, Andrew PW. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect Immun 2002; 70:2886-90.
31. Wood WB, Smith MR. The inhibition of surface phagocytosis by the capsular "slime layer" of pneumococcus type III. J Exp Med 1949; 92:85-99.
32. Knapp S, Leemans JC, Florquin S, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167:171-9.
33. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 2001; 193:51-60.
34. McWilliam AS, Nelson D, Thomas JA, Holt PG. Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces. J Exp Med 1994; 179:1331-6.
35. Legge KL, Braciale TJ. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 2003; 18:265-77.
36. Colino J, Snapper CM. Two distinct mechanisms for induction of dendritic cell apoptosis in response to intact Streptococcus pneumoniae. J Immunol 2003; 171:2354-65.
37. Colino J, Shen Y, Snapper CM. Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms. J Exp Med 2002; 195:1-13.
38. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002; 17:341-52.
39. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94:8093-8.
40. Zwijnenburg PJ, van der Poll T, Florquin S, Roord JJ, van Furth AM. Interleuidn-10 negatively regulates local cytokine and chemokine production but does not influence antibacterial host defense during murine pneumococcal meningitis. Infect Immun 2003; 71:2276-9.
41. Ato M, Stager S, Engwerda CR, Kaye PM. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat Immunol 2002; 3:1185-91.
42. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-33.
43. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-41.
44. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-702.